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ABSTRACT
High expression of mitofusin-2 (MFN2), a mitochondrial fusion protein, has been frequently 
associated with poor prognosis of patients with cervical cancer. Here, we aimed to identify 
the function of MFN2 in cervical cancer to understand its influence on disease prognosis. 
To this end, from cervical adenocarcinoma, we performed an MTT assay and quantitative 
RT-PCR (qRT-PCR) analysis to assess the effects of MFN2 on the proliferation and of 
HeLa cells. Then, colony-formation ability and tumorigenesis were evaluated using a 
tumor xenograft mouse model. The migration ability related to MFN2 was also measured 
using a wound healing assay. Consequently, epithelial-mesenchymal transition (EMT) of 
MFN2-knockdowned HeLa cells originating from adenocarcinoma. markers related to 
MFN2 were assessed by qRT-PCR. Clinical data were analyzed using cBioPortal and The 
Cancer Genome Atlas. We found that MFN2 knockdown reduced the proliferation, colony 
formation ability, migration, and in vivo tumorigenesis of HeLa cells. Primarily, migration 
of MFN2-knockdowned HeLa cells decreased through the suppression of EMT. Thus, we 
concluded that MFN2 facilitates cancer progression and in vivo tumorigenesis in HeLa cells. 
These findings suggest that MFN2 could be a novel target to regulate the EMT program 
and tumorigenic potential in HeLa cells and might serve as a therapeutic target for cervical 
cancer. Taken together, this study is expected to contribute to the treatment of patients with 
cervical cancer.
Keywords: MFN2; Oncogene; Epithelial mesenchymal transition
INTRODUCTION
Cervical cancer is the second most common cancer among women worldwide, accounting 
for approximately 85% of cervical cancer cases in developing countries (1). Cervical cancer 
is characterized by the unregulated proliferation, migration, and invasion of cervical cells 
(1). Cervical cancer accounts for 12% of all cancers worldwide and is the most common 
gynecological malignancy globally (2). High-risk human papillomavirus and various factors, 
such as sexual or reproductive, environmental or lifestyle-risk, and genetic factors, contribute 
towards the development of cervical cancer (3). However, the prognosis of cervical cancer is 
still lacking, and the molecular mechanism underlying its progression is unclear.
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Mitochondria are essential organelles involved in various metabolic functions, including energy 
production via oxidative phosphorylation. In cells, mitochondria undergo frequent fission 
and fusion processes. These play an important role in maintaining mitochondrial function 
during metabolic or environmental stress (4). The balance between mitochondrial fission 
and fusion affects mitochondrial morphology and function (5). MFN2, a protein located on 
the outer mitochondrial membrane (OMM), plays a crucial role in mitochondrial fusion and 
contributes to the maintenance and activity of mitochondria (6). The OMM GTPase MFN2 
was initially identified in the vascular smooth muscle cells of spontaneously hypertensive rats 
(7). Several mutations in MFN2 are associated with Charcot-Marie-Tooth disease type 2A (8). 
Moreover, altered MFN2 expression is related to various pathological conditions, including 
diabetes (9), obesity (10), atherosclerosis (6), Alzheimer's disease (11), Parkinson's disease (8), 
cardiomyopathy (12), and cancer (10). MFN2 is associated with cancer progression; however, its 
role in cancer remains unclear. Several studies have indicated that MFN2 is a tumor suppressor; 
for instance, MFN2 expression is lower in lung (13), colorectal (10), gastric (11), and liver 
(14) cancer tissues than in normal tissues. In a recent study, MFN2 knockdown in MCF7 and 
A549 cells elevated the proliferation, colony formation ability, and invasion of cancer cells 
(15). Additionally, overexpression of MFN2 in urinary bladder carcinoma cell lines inhibited 
the proliferation of cancer cells by inducing cell cycle arrest and apoptosis (16). However, a 
recent study showed that MFN2 acts as an oncogene in gastric cancer (17). Furthermore, MFN2 
reportedly inhibits the proliferation, migration, and invasion of lung adenocarcinoma cells (18). 
Therefore, it is necessary to identify the role of MFN2 in cancer pathogenesis.
In a previous study, we showed a positive association between MFN2 expression and cervical 
cancer pathogenesis through an MFN2 knockdown system using small interfering RNA 
(siRNA) (19). However, our previous study was unsuitable for long-term experiments because 
the MFN2 knockdown system using siRNA induced a transient decrease in MFN2 expression. 
For this reason, in the present study, we performed long-term experiments on a tumor 
xenograft model generated through the MFN2 knockdown system using short hairpin RNA 
(shRNA). This study aimed to propose a correlation between MFN2 expression and cervical 
cancer progression.
MATERIALS AND METHODS
Cell lines and culture
HeLa cell lines originating from adenocarcinoma were cultured in Roswell Park Memorial 
Institute (RPMI)-1640 medium (Cytiva, Marlborough, MA, USA) containing 10% fetal bovine 
serum (FBS; Atlas Biologicals, Fort Collins, CO, USA), 100 U/ml penicillin, and 0.1 mg/
ml streptomycin-amphotericin B (Lonza, Basel, Switzerland). Puromycin (2 µg/ml; Sigma-
Aldrich, St. Louis, MO, USA) was added to the medium to maintain RNA interference in 
HeLa cells. The cells were incubated at 37°C with 5% CO2. 
Immunocytochemistry
HeLa cells (0.2×105 cells/well) were plated onto coverslips in a 12-well plate, fixed with 4% 
paraformaldehyde, and washed with PBS. The cells were permeabilized with 0.2% Triton 
X-100 in PBS and blocked with 1% BSA for 1 h at room temperature. Cells were then incubated 
with the diluted primary Ab, in 1% BSA, against MFN2 (1:200) (Abcam, Cambridge, United 
Kingdom) at 4°C overnight. Then, the cells were washed thrice with PBS and incubated with 
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a secondary Ab (1:1,000), in 1% BSA, for 1 h at room temperature. After washing, the cells on 
coverslips were mounted using a mounting medium and analyzed under a microscope at the 
indicated magnifications.
shRNA treatment
For shRNA treatment, HeLa cells were transduced with MFN2-human shRNA lentiviral 
particles (TL311490VA_ GAGGTTCTTGACTCACTTCAGAGCAAA GC or TL311490VB_ 
TCAAGTGAGGATGTTTGAGTTTCAGAATT). A scrambled lentiviral shRNA was used as the 
negative control for MFN2 knockdown (TR30021V; OriGene, Korea).
Proliferation assay
A proliferation assay was performed to investigate whether the expression of MFN2 affects 
the viability of HeLa cells (20). Proliferation was assessed at three time points: 24, 48, and 72 
h. HeLa cells were seeded, at a density of 3×103 cells per well, in 96-well plates (SPL, Pocheon, 
Korea). Then, thiazolyl blue tetrazolium bromide (MTT) solution (Sigma-Aldrich) was diluted 
with serum-free RPMI-1640 and added to the wells, and the plates were incubated at 37°C and 
5% CO2 for 3 h in the dark. Formazan crystals were solubilized in DMSO (VWR, Radnor, PA, 
USA). The absorbance was measured at 540 nm using a microplate reader with the SoftMax® 
Pro software (Molecular Devices, San Jose, CA, USA).
Colony formation assay
A colony formation assay was performed to determine whether MFN2 expression affects 
the colony-forming ability of HeLa cells (21). HeLa cells were seeded at 800 cells per well 
in 6-well plates (SPL), and RPMI-1640 medium containing 2 µg/ml puromycin was changed 
every other day. The plates were incubated at 37°C with 5% CO2 for 10 days. Formed colonies 
were fixed with 95% ethanol at 4 °C overnight and stained with 0.25% crystal violet (Sigma-
Aldrich), diluted with 20% methanol, at room temperature overnight. The cells were viewed 
under an inverted research microscope (ECLIPSE Ti2 microscope, Nikon, Tokyo, Japan). The 
obtained images were quantified using the ImageJ software (18).
Soft agar assay
A soft agar assay was performed to determine whether MFN2 expression affects the 
anchorage-independent colony-forming ability of HeLa cells. HeLa cells were seeded, at a 
density of 1×104 cells per well, in a 6-well plate (SPL) containing 1 ml of 0.3% low-melting 
agar in 2× RPMI, supplemented with 20% FBS, and overlaid on a layer containing 1 ml of 1% 
agar in the same medium. Two weeks later, visible and viable colonies containing >50 cells 
were counted from five different fields using a stereomicroscope. Representative colonies 
were photographed. The experiments were performed in triplicate.
Spheroid formation assay
To assess whether MFN2 affects the spheroid-forming ability of HeLa cells, a spheroid 
formation assay was performed. Briefly, 1×104 cells were resuspended in medium using a 
25-gauge syringe needle for single-cell suspensions. The cells were pelleted, washed with 
cold PBS, and filtered again with a syringe to obtain single-cell suspensions. The cells were 
suspended in 2 ml of DMEM/F12 medium (WelGENE, Gyeongsan, Korea), supplemented 
with 1% PSA, 2% B27, 20 ng/ml EGF, 10 ng/ml FGFb, 4 µg/ml heparin, and 5 µg/ml insulin, 
and then seeded in Ultra-Low attachment 6-well plates (Corning, NY, USA). Then, the cells 
were maintained at 37°C in a 5% CO2 incubator for 48 h, and the number of spheroids with 
diameters greater than 100 µm was counted.
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Migration assay
A migration assay was conducted to determine whether MFN2 expression affects the 
migration ability of HeLa cells (19). Cells in each group were seeded at different densities 
until 80%–90% confluent because the proliferation rate of MFN2-knockdowned HeLa cells 
was slower than that of the control cells. HeLa cells were seeded at a density of 2×105 cells/
well for Scr-shRNA, 3×105 cells/well for MFN2-shRNA-1, and 4×105 cells/well for MFN2-
shRNA-2 in 24-well plates (SPL). When the HeLa cells reached 80%–90% confluency after 
overnight incubation, the wounds were challenged with 200 µl pipette tips sterilized with an 
alcohol lamp. Images were captured at 0, 24, and 30 h using the CellSens software (Olympus, 
Tokyo, Japan).
Western blotting
Western blot analysis was conducted to determine whether MFN2 was knocked down in HeLa 
cells at the protein level (22). HeLa cell lysates were extracted, and SDS-PAGE was performed 
to separate proteins by molecular weight. The resolved proteins were transferred onto 
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA), and after blocking with skimmed 
milk for 1 h at room temperature, the membranes were incubated at 4°C overnight with an 
anti-MFN2 Ab (Abcam, Cambridge, United Kingdom) and anti-β-actin Ab (Cell Signaling, 
Danvers, MA, USA) at a 1:1,000 dilution in 5% blocking solution. Each sample was incubated 
with the corresponding secondary Abs, and protein bands were visualized using an enhanced 
chemiluminescence detection system (GW Vitek, Seoul, Korea).
Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from HeLa cells using TRIzolTM reagent (Invitrogen, Waltham, MA, USA), 
and cDNA was synthesized using AccuPower RT PreMix (Bioneer, Daejeon, Korea) following the 
manufacturer's protocol. qRT-PCR was performed using the StepOnePlus system with TB Green 
Premix Ex Taq II (Takara, Tokyo, Japan). The following primers were used for qRT-PCR: MFN2: 
forward, 5′-GACCTTTGCTCATCTGTGTC-3′ and reverse, 5′-TCCAACCAACCGGCTTTATTC-3′; 
β-actin: forward, 5′-ATAGCACAGCCTGGATAGCAACGTAC-3′ and reverse, 
5′-CACCTTCTACAATGAGCTGCGTGTG-3′. The following primers for proliferation 
markers were used: PCNA: forward, 5′-GGCGTGAACCTCACCAGTAT-3′ and reverse, 
5′-TTCTCCTGGTTTGGTGCTTC-3′; Ki67: forward, 5′-AAGCCCTCCAGCTCCTAGTC-3′ 
and reverse, 5′-GCAGGTTGCCACTCTTTCTC-3′. The following primers for EMT 
markers were used: Claudin1 (CLDN1): forward, 5′-GGCTGCTTTGCTGCAACTGTC-3′ 
and reverse, 5′-GAGCCGTGGCACCTTACACG-3′; Occludin (OCLN): forward, 
5′-CGGTCTAGGACGCAGCAGAT-3′ and reverse, 5′-AAGAGGCCTGGATGACATGG-3′; 
Snail (Snail1): forward, 5′-TCTCTGAGGCCAAGGATCTC-3′ and reverse, 
5′-CTTCGGATGTGCATCTTGAG-3′; E-cadherin: forward, 5′-GGTTTTCTACAGCATCACCG-3′ 
and reverse, 5′-GCTTCCCCATTTGATGACAC-3′; N-cadherin: forward, 
5′-TGAAACGGCGGGATAAAGAG-3′ and reverse, 5′-GGCTCCACAGTATCTGGTTG-3′; Axin2: 
forward: 5′-AAGGGCCAGGTCACCAAAC-3′ and reverse, 5′-CCCCCAACCCATCTTCGT-3′.
Tumor xenograft model
Female BALB/c nude mice (5-wk-old) were purchased from Orient Bio Inc. (Seongnam, 
Korea). Tumor models were generated via subcutaneous injection of 3×106 HeLa cells in 
the flanks of mice. Tumor volumes were measured using calipers once every 2 days and 
calculated using the following formula: V=(L×W2)/2 (L, length; W, width). For puromycin 
treatment, 10 mg/kg puromycin was subcutaneously injected every 2 days for 18 days. Mice 
were sacrificed by CO2 inhalation at the end of the experiment. All mice were maintained 
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under specific-pathogen-free conditions in the animal establishment at the Avison 
Biomedical Research Center in Yonsei University College of Medicine.
Bioinformatic analysis
The effect of MFN2 expression in patients with cervical carcinoma was analyzed using 
cBioPortal and the Human Genome Atlas for cancer genomics. Information on cervical 
squamous cell carcinoma and endocervical adenocarcinoma was obtained from The Cancer 
Genome Atlas (TCGA) and Firehose Legacy. In the genomic profiles, mutations and putative 
copy number alterations from GISTIC were selected. Additionally, mRNA expression z-scores 
relative to the diploid samples were selected. cBioPortal was used to analyze the mutation count 
and survival rate of patients with cervical cancer depending on the expression levels of MFN2.
Statistical analysis
Statistical analyses were performed using the IBM SPSS Statistics 26 software. Statistically 
significant differences among groups were determined with one-way ANOVA followed by 
Dunnett's post hoc test (for proliferation, migration, and colony formation assays). Data are 
expressed as the mean±SD of values from at least three independent experiments. Statistical 
significance was determined using two-tailed Student's t-tests. Data are expressed as the 
mean±SEM for tumor volume. Statistical significance was set at p<0.05.
Ethics approval and consent to participate
All animal experiments were approved by the Institutional Animal Care and Use Committee 
of Yonsei University Health System (IACUC 2017-0353).
RESULTS
MFN2 knockdown suppressed the growth of HeLa cells
Using immunohistochemistry, we confirmed that MFN2 was expressed in HeLa cells (Fig. 1A). 
Then, MFN2 was knocked down in HeLa cells via shRNA-mediated transfection. Western blot 
analysis revealed that MFN2-shRNA transfection inhibited MFN2 expression in HeLa cells 
compared to that in non-transfected wild-type cells and scrambled shRNA control cells (Scr-
shRNA) (Fig. 1B).
Compared to that of the Scr-shRNA-transfected HeLa cells, the viability of MFN2-shRNA-
transfected cells was significantly decreased at 48–72 h (MFN2-shRNA-1, p<0.001) and 24–72 
h (MFN2-shRNA-2, p<0.001) after transfection (Fig. 2A). Furthermore, HeLa cells transfected 
with MFN2-shRNA showed significantly reduced mRNA levels of Ki67 (both p<0.001) and 
PCNA (both p<0.001) relative to those in the Scr-shRNA group (Fig. 2B). A colony formation 
5/12https://doi.org/10.4110/in.2021.21.e30

















Figure 1. Representative expression of MFN2 in HeLa cells. (A) Immunocytochemistry analysis was conducted to confirm the expression of MFN2 in HeLa cells 
(original magnification, 40×, 200×, 400×, and 1,000×; scale bar=10 µm). (B) The protein expression of MFN2 was compared between MFN2-shRNA-transfected 
cells and Scr-shRNA in HeLa cells over time via western blotting. All experiments were performed in triplicate.
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Figure 2. MFN2 knockdown suppressed the growth of HeLa cells. (A) The viability of MFN2-knockdowned cells was significantly reduced compared to that of 
Scr-shRNA HeLa cells at the indicated time points. (B) The mRNA expression of Ki-67 and PCNA was significantly reduced in MFN2-knockdowned cells compared 
to that in Scr-shRNA HeLa cells. The results were analyzed using ANOVA followed by Dunnett's post hoc test (***p<0.001 vs. Scr-shRNA). (C) Colony-forming 
ability was significantly reduced in MFN2-knockdowned cells compared to that in the Scr-shRNA HeLa cells. (D) The number of colonies was significantly 
decreased in MFN2-knockdowned cells compared to that in the Scr-shRNA HeLa cells (original magnification, 40×; scale bar=500 µm). (E) Spheroid formation 
was significantly inhibited in MFN2-knockdowned cells compared to that in Scr-shRNA HeLa cells at 48 h (original magnification, 100×; scale bar=200 µm). 
Quantitative spheroid area indicates the mean±SD of values from two independent experiments, each of which was conducted in triplicate (Scr-shRNA; n=9, 
MFN2-shRNA-1; n=13, MFN2-shRNA-2; n=14). The results were analyzed using one-way ANOVA followed by Dunnett's post hoc test (***p<0.001 vs. Scr-shRNA). (F) 
The tumorigenic ability was significantly attenuated in MFN2-shRNA-1 HeLa cells compared to that in the Scr-shRNA HeLa cells. The results were analyzed using 
two-tailed Student's t-test (*p<0.05 and ***p<0.001 vs. Scr-shRNA) (n=10 mice per group). All experiments were performed in triplicate.
assay was performed to investigate the effect of MFN2 on HeLa cell colonization. Transfection 
of MFN2-shRNA remarkably suppressed colony formation in HeLa cells, as measured by colony 
area (both p<0.001) and colony intensity (both p<0.001) (Fig. 2C). Consistently, compared 
with that in the corresponding control groups, transfection of MFN2-shRNA significantly 
decreased the number of colonies of HeLa cells (both p<0.001) (Fig. 2D). Additionally, the 
3-D spheroid formation assay was performed to examine cancer stemness; MFN2 knockdown 
significantly inhibited the spheroid formation ability of HeLa cells compared to that in the 
control. These results imply that MFN2 exhibits cancer stem cell-like properties in HeLa 
cells (Fig. 2E). Next, we examined the effect of MFN2 knockdown on tumorigenesis in tumor 
xenograft models. MFN2 knockdown significantly suppressed in vivo tumor growth (p<0.05) 
and relative tumor weight (p<0.001) of HeLa cells, whereas the body weight was unaffected 
(Fig. 2F). These results suggest that MFN2 positively regulates tumor growth and progression.
MFN2 knockdown inhibited the migration of HeLa cells
The migratory properties of cancer cells contribute to a poor prognosis in patients. In this 
study, we investigated the effects of MFN2 on cell migration. The wound-healing assay 
demonstrated that MFN2 knockdown in HeLa cells significantly suppressed cell migration 
(Fig. 3A). Quantitative analysis of the wound closure rate of HeLa cells revealed that MFN2-
shRNA transfection significantly inhibited HeLa cell migration, as measured at 24 h (both 
p<0.001) and 30 h (both p<0.001) post scratch wounding (Fig. 3A). These findings suggest 
that MFN2 promotes cancer cell migration.
MFN2 knockdown suppressed Snail-mediated EMT in HeLa cells
EMT is an important biological process implicated in the initiation of metastasis in cancer 
progression. It is characterized by the loss of the epithelial marker E-cadherin and the gain 
of the mesenchymal marker N-cadherin (23). We evaluated whether there were differences 
in the mRNA levels of EMT markers in HeLa cells after MFN2 knockdown. The relative 
mRNA levels of epithelial markers, Claudin1 (MFN2-shRNA-1, p<0.05; MFN2-shRNA-2, 
p<0.005), Occludin (MFN2-shRNA-1, p<0.05; MFN2-shRNA-2, p<0.001), and E-cadherin 
(MFN2-shRNA-1, p<0.001; MFN2-shRNA-2, p<0.001), were significantly increased in MFN2-
knockdowned groups compared with those in the scrambled shRNA control (Fig. 3B). In 
contrast, the relative mRNA levels of mesenchymal markers, N-cadherin (MFN2-shRNA-1, 
p<0.005; MFN2-shRNA-2, p<0.005) and Axin2 (MFN2-shRNA-1, p<0.001; MFN2-shRNA-2, 
p<0.001), were significantly decreased in the MFN2-knockdowned groups (Fig. 3C). 
Additionally, mRNA levels of the EMT-related transcription factor Snail1 (MFN2-shRNA-1, 
p<0.001; MFN2-shRNA-2, p<0.001) were significantly decreased after MFN2 knockdown in 
HeLa cells (Fig. 3D). These results suggest that MFN2 acts as a positive regulator of Snail-
mediated EMT in HeLa cells.
High MFN2 expression predicted poor prognosis in patients with cervical cancer
To determine the effects of high or low MFN2 expression in patients with cervical cancer, 
the survival curve for cervical cancer patients with high or low MFN2 mRNA expression 
was generated from cBioPortal (https://www.cbioportal.org/). We selected human cervical 
cancer patient samples (n=190) from cervical squamous cell carcinoma and endocervical 
adenocarcinoma from TCGA. The mutation count was higher in the group with high MFN2 
expression than in the group with low MFN2 expression (Supplementary Fig. 1A). As shown 
in Supplementary Fig. 1B, cervical cancer patients with high MFN2 expression showed a 
poor prognosis compared to patients with low MFN2 expression. These results imply that 
increased levels of MFN2 are associated with poor prognosis in patients with cervical cancer.
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Figure 3. MFN2 knockdown inhibited HeLa cell migration. (A) Cell motility was significantly reduced in MFN2-knockdowned cells compared to that in Scr-shRNA 
HeLa cells at the indicated time points (original magnification, 100×; scale bar=200 µm). Quantitative results indicate the mean±SD of values from three independent 
experiments, which were conducted in triplicate (n=9). The results were analyzed with ANOVA followed by Dunnett's post hoc test (***p<0.001 vs. Scr-shRNA). (B) 
The mRNA expression of Claudin1, Occludin, and E-cadherin was significantly increased in MFN2-knockdowned cells compared to that in Scr-shRNA HeLa cells. (C) 
The mRNA expression of Axin2 and N-cadherin was significantly decreased in MFN2-knockdowned cells compared to that in Scr-shRNA HeLa cells. (D) The mRNA 
expression of Snail1 was significantly decreased in MFN2-knockdowned cells compared to that in Scr-shRNA HeLa cells. The results were analyzed using one-way 
ANOVA followed by Dunnett's post hoc test (*p<0.05, **p<0.005, ***p<0.001 vs. Scr-shRNA). All experiments were performed in triplicate.
DISCUSSION
In this study, we investigated whether MFN2 promotes cancer progression in cervical cancer 
and found that this mitochondrial gene serves as an oncogene in the cervix. The disease 
prognosis in patients with cervical cancer positively correlated with the expression levels of 
MFN2. Additionally, the proliferation ability decreased when MFN2 was knocked down in 
HeLa and SiHa cell lines, which are cervical adenocarcinoma and squamous cell carcinoma 
cell lines, respectively (24). Most tumors are associated with mitochondrial metabolic 
dysfunction, which involves excessive fusion and deficient fission under MFN2 overexpression 
conditions (25,26). Increasing evidence suggests that during cancer progression, cells 
produce ATP via the mitochondrial oxidative phosphorylation similar to that in normal cells, 
thus reversing the Warburg effect (27,28). As indicated by Li et al. (27), MFN2 knockdown 
in non-small cell lung cancer (NSCLC) reduced oxygen consumption, thereby suppressing 
malignant characteristics such as proliferation, migration, and tumorigenesis (25). Moreover, 
we discovered that MFN2 promoted Snail-mediated EMT, which leads to the progression 
of diverse oncogenic functions, including tumor initiation, cancer progression, stemness, 
migration, metastasis, and resistance to cancer therapy (29,30).
EMT is regulated by various signaling pathways, among which canonical Wnt signaling is a 
critical pathway that is dependent on the transcription of β-catenin (31,32). In bladder cancer 
cells, MFN2 inhibits cell proliferation and invasion via the Wnt/β-catenin pathway (33), and 
in neuronal disease, stress-activated MFN2 regulates the Wnt signaling pathway to exert a 
neuroprotective function through synapse remodeling (34). Ras signaling is also correlated 
with MFN2, which regulates cell proliferation, the cell cycle, and morphology by controlling the 
morphology and tethering of mitochondria and the endoplasmic reticulum (35). In fibroblasts, 
MFN2 overexpression inhibits cell proliferation and procollagen expression through the Ras-
Raf-ERK axis underlying pelvic organ prolapse development (36). Several reports have suggested 
that modulating MFN2 regulation could be a potential therapeutic strategy against lung injury 
caused by endotoxins and breast cancer through the PI3K/Akt pathway (37,38). In hypoxic 
pulmonary hypertension, MFN2 controls pulmonary artery smooth muscle cell proliferation 
by regulating the PI3K/Akt pathway (39). Moreover, MFN2 regulates the TGF-β pathway, which 
is the main driver of carcinogenesis (40), and inhibits potential chronic rejection and cellular 
senescence (41,42). Another report suggested that the dysregulation of Smad, a nuclear-shuttling 
transcriptional mediator of TGF-β signaling, and MFN2 causes malignant tumor growth and 
neurodegenerative disorders (43). Finally, MFN2 is indicated as a p53-inducible target gene that 
suppresses cell proliferation, facilitates apoptosis, and regulates tumor suppression (44).
Benzyl isothiocyanate (BITC), a natural isothiocyanate with antimicrobial activity (45,46), 
potently inhibits cell motility and matrix metalloproteinase-2 activity in murine melanoma 
B16F10 cells (46). The inhibition of mitochondrial fusion in breast cancer cell apoptosis 
by BITC has been reported as an early and important phenomenon. The protein levels 
of MFN1 and MFN2 were markedly reduced after 2, 4, and 6 h of treatment with BITC in 
both MDA-MB-231 and MCF-7 breast cancer cells (47). Although BITC reduces the levels of 
mitochondrial fission-and fusion-related proteins in breast cancer cells, the effect of BITC on 
cancer-related signaling pathways is unclear. Therefore, future studies on MFN2 and cancer 
signaling using MFN2 inhibitors are needed.
In conclusion, our study results showed that MFN2 acts as an oncogene that promotes 
cervical cancer progression, suggesting that MFN2 could be a new target gene for cervical 
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cancer treatment. Furthermore, more data related to the incidence of cervical cancer and its 
association with MFN2 expression might contribute to the identification of novel biomarkers 
for patients with cervical cancer.
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SUPPLEMENTARY MATERIAL
Supplementary Figure 1
Cervical cancer patients with high MFN2 expression showed a poor prognosis. In silico data 
from patients with cervical cancer correlated with MFN2 expression. (A) Comparison of the 
mutation count between the groups with high and low MFN2 expression. (B) The overall 
survival curve for cervical cancer patients with high and low MFN2 expression was acquired 
from cBioPortal (https://www.cbioportal.org/).
Click here to view
REFERENCES
 1. Dasari S, Wudayagiri R, Valluru L. Cervical cancer: biomarkers for diagnosis and treatment. Clin Chim Acta 
2015;445:7-11. 
PUBMED | CROSSREF
 2. Senapathy JG, Umadevi P, Kannika PS. The present scenario of cervical cancer control and HPV 
epidemiology in India: an outline. Asian Pac J Cancer Prev 2011;12:1107-1115.
PUBMED
 3. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet 2019;393:169-182. 
PUBMED | CROSSREF
 4. Hernández-Alvarez MI, Thabit H, Burns N, Shah S, Brema I, Hatunic M, Finucane F, Liesa M, Chiellini C, 
Naon D, et al. Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle 
PGC-1alpha/Mitofusin-2 regulatory pathway in response to physical activity. Diabetes Care 2010;33:645-651. 
PUBMED | CROSSREF
 5. Bereiter-Hahn J, Vöth M. Dynamics of mitochondria in living cells: shape changes, dislocations, fusion, 
and fission of mitochondria. Microsc Res Tech 1994;27:198-219. 
PUBMED | CROSSREF
 6. Chien KR, Hoshijima M. Unravelling Ras signals in cardiovascular disease. Nat Cell Biol 2004;6:807-808. 
PUBMED | CROSSREF
 7. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of 
amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: 
implications for neuronal damage. Hum Mol Genet 2011;20:2495-2509. 
PUBMED | CROSSREF
 8. Lee S, Sterky FH, Mourier A, Terzioglu M, Cullheim S, Olson L, Larsson NG. Mitofusin 2 is necessary for 
striatal axonal projections of midbrain dopamine neurons. Hum Mol Genet 2012;21:4827-4835. 
PUBMED | CROSSREF
 9. Chen Y, Liu Y, Dorn GW 2nd. Mitochondrial fusion is essential for organelle function and cardiac 
homeostasis. Circ Res 2011;109:1327-1331. 
PUBMED | CROSSREF
10/12https://doi.org/10.4110/in.2021.21.e30
MFN2 for Cancer Progression
https://immunenetwork.org
 10. Cheng X, Zhou D, Wei J, Lin J. Cell-cycle arrest at G2/M and proliferation inhibition by adenovirus-
expressed mitofusin-2 gene in human colorectal cancer cell lines. Neoplasma 2013;60:620-626. 
PUBMED | CROSSREF
 11. Zhang GE, Jin HL, Lin XK, Chen C, Liu XS, Zhang Q, Yu JR. Anti-tumor effects of Mfn2 in gastric cancer. 
Int J Mol Sci 2013;14:13005-13021. 
PUBMED | CROSSREF
 12. Xu K, Chen G, Li X, Wu X, Chang Z, Xu J, Zhu Y, Yin P, Liang X, Dong L. MFN2 suppresses cancer 
progression through inhibition of mTORC2/Akt signaling. Sci Rep 2017;7:41718. 
PUBMED | CROSSREF
 13. Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C, 
Archer SL. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J 
2012;26:2175-2186. 
PUBMED | CROSSREF
 14. Wang W, Lu J, Zhu F, Wei J, Jia C, Zhang Y, Zhou L, Xie H, Zheng S. Pro-apoptotic and anti-proliferative 
effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells. Med Oncol 2012;29:70-76. 
PUBMED | CROSSREF
 15. Lin Z, Lin Y, Shen J, Jiang M, Hou Y. Flavonoids in Ageratum conyzoides L. Exert potent antitumor effects on 
human cervical adenocarcinoma HeLa cells in vitro and in vivo. BioMed Res Int 2020;2020:2696350. 
PUBMED | CROSSREF
 16. Jin B, Fu G, Pan H, Cheng X, Zhou L, Lv J, Chen G, Zheng S. Anti-tumour efficacy of mitofusin-2 in 
urinary bladder carcinoma. Med Oncol 2011;28 Suppl 1:S373-S380. 
PUBMED | CROSSREF
 17. Fang CL, Sun DP, Chen HK, Lin CC, Hung ST, Uen YH, Lin KY. Overexpression of mitochondrial GTPase 
MFN2 represents a negative prognostic marker in human gastric cancer and its inhibition exerts anti-
cancer effects. J Cancer 2017;8:1153-1161. 
PUBMED | CROSSREF
 18. Guzmán C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically 
quantify colony formation in clonogenic assays. PLoS One 2014;9:e92444. 
PUBMED | CROSSREF
 19. Cory G. Scratch-wound assay. Methods Mol Biol 2011;769:25-30. 
PUBMED | CROSSREF
 20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and 
cytotoxicity assays. J Immunol Methods 1983;65:55-63. 
PUBMED | CROSSREF
 21. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, Showalter HD, Murai MJ, Belcher AM, 
Hartley T, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat 
Chem Biol 2012;8:277-284. 
PUBMED | CROSSREF
 22. Kurien BT, Scofield RH. Western blotting: an introduction. Methods Mol Biol 2015;1312:17-30. 
PUBMED | CROSSREF
 23. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and 
disease. Cell 2009;139:871-890. 
PUBMED | CROSSREF
 24. Ahn SY, Li C, Zhang X, Hyun YM. Mitofusin-2 expression is implicated in cervical cancer pathogenesis. 
Anticancer Res 2018;38:3419-3426. 
PUBMED | CROSSREF
 25. Ghosh P, Vidal C, Dey S, Zhang L. Mitochondria targeting as an effective strategy for cancer therapy. Int J 
Mol Sci 2020;21:21. 
PUBMED | CROSSREF
 26. Pustylnikov S, Costabile F, Beghi S, Facciabene A. Targeting mitochondria in cancer: current concepts and 
immunotherapy approaches. Transl Res 2018;202:35-51. 
PUBMED | CROSSREF
 27. Li T, Han J, Jia L, Hu X, Chen L, Wang Y. PKM2 coordinates glycolysis with mitochondrial fusion and 
oxidative phosphorylation. Protein Cell 2019;10:583-594. 
PUBMED | CROSSREF
 28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674. 
PUBMED | CROSSREF




MFN2 for Cancer Progression
https://immunenetwork.org
 30. Cho ES, Kang HE, Kim NH, Yook JI. Therapeutic implications of cancer epithelial-mesenchymal 
transition (EMT). Arch Pharm Res 2019;42:14-24. 
PUBMED | CROSSREF
 31. Gajos-Michniewicz A, Czyz M. WNT signaling in melanoma. Int J Mol Sci 2020;21:21. 
PUBMED | CROSSREF
 32. Taciak B, Pruszynska I, Kiraga L, Bialasek M, Krol M. Wnt signaling pathway in development and cancer. J 
Physiol Pharmacol 2018;69:69.
PUBMED
 33. Pang G, Xie Q, Yao J. Mitofusin 2 inhibits bladder cancer cell proliferation and invasion via the Wnt/β-
catenin pathway. Oncol Lett 2019;18:2434-2442. 
PUBMED | CROSSREF
 34. Palomera-Avalos V, Griñán-Ferré C, Puigoriol-Ilamola D, Camins A, Sanfeliu C, Canudas AM, Pallàs 
M. Resveratrol protects samp8 brain under metabolic stress: focus on mitochondrial function and wnt 
pathway. Mol Neurobiol 2017;54:1661-1676. 
PUBMED | CROSSREF
 35. de Brito OM, Scorrano L. Mitofusin-2 regulates mitochondrial and endoplasmic reticulum morphology 
and tethering: the role of Ras. Mitochondrion 2009;9:222-226. 
PUBMED | CROSSREF
 36. Wang X, Wang X, Zhou Y, Peng C, Chen H, Lu Y. Mitofusin2 regulates the proliferation and function 
of fibroblasts: the possible mechanisms underlying pelvic organ prolapse development. Mol Med Rep 
2019;20:2859-2866. 
PUBMED | CROSSREF
 37. Shi J, Yu J, Zhang Y, Wu L, Dong S, Wu L, Wu L, Du S, Zhang Y, Ma D. PI3K/Akt pathway-mediated HO-1 
induction regulates mitochondrial quality control and attenuates endotoxin-induced acute lung injury. 
Lab Invest 2019;99:1795-1809. 
PUBMED | CROSSREF
 38. Ma LI, Chang Y, Yu L, He W, Liu Y. Pro-apoptotic and anti-proliferative effects of mitofusin-2 via PI3K/Akt 
signaling in breast cancer cells. Oncol Lett 2015;10:3816-3822. 
PUBMED | CROSSREF
 39. Fang X, Chen X, Zhong G, Chen Q, Hu C. Mitofusin 2 downregulation triggers pulmonary artery smooth 
muscle cell proliferation and apoptosis imbalance in rats with hypoxic pulmonary hypertension via the 
PI3K/Akt and mitochondrial apoptosis pathways. J Cardiovasc Pharmacol 2016;67:164-174. 
PUBMED | CROSSREF
 40. Syed V. Tgf-β signaling in cancer. J Cell Biochem 2016;117:1279-1287. 
PUBMED | CROSSREF
 41. Sun Q, Chen L, Zhou D, Yang Q, Song W, Chen D, Wang W. Mfn2 inhibits chronic rejection of the rat 
abdominal aorta by regulating TGF-β1 levels. Transpl Immunol 2019;55:101211. 
PUBMED | CROSSREF
 42. He H, Yu B, Liu Z, Ye G, You W, Hong Y, Lian Q, Zhang Y, Li X. Vascular progenitor cell senescence in 
patients with Marfan syndrome. J Cell Mol Med 2019;23:4139-4152. 
PUBMED | CROSSREF
 43. Kumar S, Pan CC, Shah N, Wheeler SE, Hoyt KR, Hempel N, Mythreye K, Lee NY. Activation of 
mitofusin2 by Smad2-RIN1 complex during mitochondrial fusion. Mol Cell 2016;62:520-531. 
PUBMED | CROSSREF
 44. Wang W, Cheng X, Lu J, Wei J, Fu G, Zhu F, Jia C, Zhou L, Xie H, Zheng S. Mitofusin-2 is a novel direct 
target of p53. Biochem Biophys Res Commun 2010;400:587-592. 
PUBMED | CROSSREF
 45. Abdel-Kader MS, Kamal YT, Alam P, Alqarni MH, Foudah AI. Quantitative analysis of benzyl 
isothiocyanate in Salvadora persica extract and dental care herbal formulations using reversed phase C18 
high-performance liquid chromatography method. Pharmacogn Mag 2017;13 Suppl 3:S412-S416. 
PUBMED | CROSSREF
 46. Lai KC, Hsiao YT, Yang JL, Ma YS, Huang YP, Chiang TA, Chung JG. Benzyl isothiocyanate and phenethyl 
isothiocyanate inhibit murine melanoma B16F10 cell migration and invasion in vitro. Int J Oncol 
2017;51:832-840. 
PUBMED | CROSSREF
 47. Sehrawat A, Croix CS, Baty CJ, Watkins S, Tailor D, Singh RP, Singh SV. Inhibition of mitochondrial 
fusion is an early and critical event in breast cancer cell apoptosis by dietary chemopreventative benzyl 
isothiocyanate. Mitochondrion 2016;30:67-77. 
PUBMED | CROSSREF
12/12https://doi.org/10.4110/in.2021.21.e30
MFN2 for Cancer Progression
https://immunenetwork.org
